Source disclosure: January 30, 2026
Tokuyama Corporation [4043.T]
TOKYO — Tokuyama Corporation reported its third quarter earnings for the fiscal year ending March 2026 on January 30, 2026. The company's consolidated results for the nine months ended December 31, 2025, showed mixed performance compared to the same period last year.
For the three-month period ending December 31, 2025, Tokuyama recorded a sales 524 billion, marking a slight decrease of 0.7 percent from the previous year’s figure of ¥253.387 billion. Operating income improved significantly by 26.9 percent to ¥26.730 billion from ¥21.071 billion in the corresponding quarter of the prior year. Similarly, ordinary income increased by 24.9 percent to ¥27.443 billion from ¥21.980 billion. Net income attributable to shareholders of the parent company rose by 11.5 percent to ¥18.870 billion from ¥16.918 billion in the comparable quarter of the previous year.
The company also noted that comprehensive income for the current quarter was ¥24.494 billion, representing an increase of 58.1 percent over the previous year's figure of ¥15.494 billion. On a per-share basis, net income for the quarter amounted to ¥262.28 per share, up from ¥235.15 per share in the same quarter last year. As of the end of the third quarter, the company's 339 billion, while equity reached ¥291.950 billion, resulting in a capital adequacy ratio of 49.8 percent and a book value per share of ¥3,851.04.
Regarding dividends, Tokuyama maintained its dividend payout policy. For the fiscal year ending March 2025, the company paid out ¥100 per share, split evenly between the second and fourth quarters. In the ongoing fiscal year, it has already declared a dividend of ¥60 per share for the first half-year, with expectations to pay another ¥60 per share by the end of the year, totaling ¥120 per share. There have been no changes to the previously announced dividend forecast.
Looking ahead, Tokuyama revised its full-year forecasts for the fiscal year ending March 2026. Sales are now expected to reach ¥351.500 billion, a 2.5 percent increase from the previous year. Operating profit is projected to rise by 30.1 percent to ¥39.000 billion, while ordinary profit is anticipated to grow by 31.8 percent to ¥39.000 billion. Net income attributable to shareholders of the parent company is estimated to be ¥27.500 billion, marking a 17.6 percent growth from the previous year. This translates to an earnings per share of ¥382.23, reflecting a robust improvement over the previous year's figures. These projections represent adjustments made since the latest announcement on January 30, 2026, regarding the revision of the annual business outlook.
In addition to these financial highlights, Tokuyama disclosed several significant changes affecting its consolidated scope during this reporting period. Seven new companies were added, including Aiken Toyo Medical Instruments (Suzhou) Co., Ltd., Tokuyama Life Sciences Co., Ltd., MBL Shenzhen Biotech Co., Ltd., MBL Beijing Biotech Co.,
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing